CTRI/2015/05/005770已完成3 期
Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India
Sanofi Pasteur SA0 个研究点目标入组 400 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Aged 6 months or older on the day of inclusion
- •- For subjects aged 6 to 35 months only: born at full term of pregnancy (>=37 weeks) or birth weight >=2.5 kg or both
- •- Informed consent form has been signed and dated by the subjects / subjectsâ?? parent(s) or another legally acceptable representative and by an independent witness, if required by local regulations. For subjects aged 7 to 17 years of age, assent form has been signed and dated by the subject
- •- Subject / subjectsâ?? parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.
排除标准
- •For subjects aged 9 years or older only: Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)
- •Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks following any trial vaccination (except oral poliomyelitis vaccine [OPV] received during national immunization days)
- •For subjects aged 9 years or older only: previous vaccination against influenza (in the previous 9 months) with any influenza vaccine.
- •For subjects aged 6 months to 8 years only: previous priming with any influenza vaccine (i.e., subjects who received 2 doses for at least 1 previous influenza season)
- •Receipt of immune globulins, blood or blood-derived products in the past 3 months
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •Self-reported history of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, after questioning
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- •Self-reported thrombocytopenia or as reported by the parent/legally acceptable representative, contraindicating intramuscular (IM) vaccination
- •Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
- •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- •For subjects aged 9 years or older only: current alcohol abuse or drug addiction
- •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- •Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature >= 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
- •Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
研究者
相似试验
已完成
不适用
Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind studyETEC disease.Infections and InfestationsEnterotoxigenic E. coli infectionISRCTN05087777Berna Biotech Ltd (Switzerland)50
Unknown
3 期
Immunogenicity of a single standard dose versus a double standard dose of inactivated trivalent influenza vaccine in patients on peritoneal dialysis: Open labelled Randomized control trialSafety-End stage kidney disease patients on peritoneal dialysis treatment -Healthy volunteerHigh dose influenza vaccinePeritoneal dialysisHemagglutininCellular immunityVaccinationChronic kidney diseaseTCTR20220526003Health Systems Research Institute(HSRI)125
已完成
2 期
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of AgeInfluenzaNCT00397215GlaxoSmithKline437
尚未招募
不适用
Immunogenicity and safety study of 1,2 doses of GSK Biologicals meningococcal vaccine MenACWY-TT (GSK134612) in toddlersPACTR201408000864165GlaxoSmithKline Biologicals900
进行中（未招募）
1 期
Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and AboveRespiratory Syncytial Virus (RSV)NCT06642558MAXVAX Biotechnology Limited Liability Company522